ACSL4 and hepatocellular carcinoma: A study that involved cell functional tests and xenografts as part of a clinical trial demonstrated that ACSL4 has an essential role in sorafenib-induced ferroptosis and may serve as a biomarker for predicting drug sensitivity in HCC [13].